How Can The GS Effex® Cell Line Increase The Potency Of Therapeutic Antibodies?

Antibody effector function can play an important role in therapeutic performance, particularly for molecules where enhanced antibody-dependent cellular cytotoxicity (ADCC) is desired. In this video, Dr. Peter O'Callaghan, Senior Director and Head of Expression System Sciences, Licensing, explains how Lonza's GS Effex® cell line is designed to support the production of antibodies with enhanced effector function.

Derived from Lonza's established CHO GS knockout platform, GS Effex® incorporates a FUT8 knockout to enable production of afucosylated antibodies. Reduced fucosylation can strengthen interactions between the antibody Fc region and Fc-gamma receptors on effector cells, driving an increased ADCC response.

The video also shows how GS Effex® integrates into Lonza's broader GS Gene Expression System®, letting customers use the same expression vectors, GS piggyBac® transposase technology, and media while incorporating the cell line into existing workflows. Dr. O'Callaghan discusses options for accessing the technology through research licensing or Lonza's development and manufacturing services.

Watch the full video to learn how GS Effex® can support the development of antibodies with enhanced ADCC while fitting seamlessly into established expression workflows.